# Interstitial lung disease on antibody-drug conjugates and targeted drugs: monitoring and management by grade

Source: https://onco.cc/protocols/interstitial-lung-disease-on-antibody-drug-conjugates-and-targeted-drugs/  
OnCo record `interstitial-lung-disease-on-antibody-drug-conjugates-and-targeted-drugs` (Protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Some cancer drugs, above all trastuzumab deruxtecan, can inflame the lungs. It can show on a scan before there are any symptoms, and it is treated by pausing or stopping the drug and, often, steroids. The rules differ from drug to drug. A new or worsening cough, breathlessness or fever needs a call to your cancer team straight away, not at the next appointment.

## Summary

Drug-induced ILD is a diagnosis of exclusion: infection, cancer progression, radiation pneumonitis and fluid overload look similar on CT. Grade 1 is a scan finding with no symptoms, grade 2 mild symptoms, grade 3 severe symptoms or a need for oxygen, grade 4 life-threatening. What happens at each grade depends on the drug, and the label of the drug being taken is the rule; the reader's own team's protocol comes first.

How common (US labels): trastuzumab deruxtecan 12% at 5.4 mg/kg, fatal in 0.9%, median onset 5.5 months; datopotamab deruxtecan 7% in lung cancer and 3.0% in breast cancer; osimertinib 4%; abemaciclib about 3%; ribociclib 1.6% in advanced breast cancer; everolimus up to 19%; sotorasib 2.2%; olaparib 1.0%. In a manufacturer-funded pooled analysis of 1150 trial patients on trastuzumab deruxtecan, 87.0% of first events came within 12 months, and the factors potentially associated with higher risk were age under 65, enrolment in Japan, a dose above 6.4 mg/kg, oxygen saturation below 95%, moderate or severe renal impairment, lung comorbidities and more than 4 years since diagnosis.

Grade 1 (no symptoms), side by side. Trastuzumab deruxtecan and datopotamab deruxtecan: withhold until fully resolved, consider prednisolone at 0.5 mg/kg/day or more, and resume at the same dose if resolved within 28 days or one dose level lower if later. Everolimus: continue without changing the dose. Abemaciclib: no dose change at grade 1 or 2. Ribociclib: no interruption at grade 1. Osimertinib: stop permanently once ILD is confirmed, whatever the grade, except after recent chemoradiotherapy, where grade 1 may be continued or interrupted and restarted. Sotorasib and olaparib: withhold on suspicion and stop permanently if confirmed.

Grade 2 and above. Deruxtecan conjugates: stop permanently and start prednisolone at 1 mg/kg/day or more for at least 14 days, then taper over at least 4 weeks. Osimertinib, sotorasib, olaparib: stopped. Everolimus: withhold at grade 2 or 3 and resume at half dose after improvement, stop at grade 4. Abemaciclib: withhold for persistent or recurrent grade 2 and resume one dose lower, stop at grade 3 or 4. Ribociclib: interrupt at grade 2 and consider a lower dose, stop at grade 3 or 4.

The expert opinion of Conte and colleagues (ESMO Open 2022, funded by Daiichi Sankyo and AstraZeneca, ungraded) adds a work-up (high-resolution CT at once, oxygen saturation, bloods, microbiology, lung function, bronchoscopy when the picture is unclear), prednisone 1 to 2 mg/kg/day at grade 2, methylprednisolone 1 to 2 mg/kg/day at grade 3, pulsed methylprednisolone 500 to 1000 mg/day for 3 days as an option at grade 4, and says infliximab, tocilizumab, mycophenolate or intravenous immunoglobulin may be considered at grade 3 if there is no improvement within 48 to 72 hours (at grade 4, infliximab, mycophenolate or immunoglobulin after 48 hours without improvement). It says the efficacy of steroids is not clearly established.

## Fields

- Kind: Protocol
- Last checked: 2026-11-17
- Also known as: drug-induced ILD; drug-induced pneumonitis; trastuzumab deruxtecan ILD; T-DXd pneumonitis; Enhertu lung inflammation; osimertinib pneumonitis; everolimus non-infectious pneumonitis; CDK4/6 inhibitor pneumonitis; DIILD

## Connected records

- protocols: [Breathlessness and cough during anticancer drug treatment: what is excluded first and how the symptom is eased](https://onco.cc/protocols/breathlessness-and-cough-during-anticancer-treatment/), [Immune-related pneumonitis from checkpoint inhibitors, by grade](https://onco.cc/protocols/irae-pneumonitis/), [Pneumocystis pneumonia (PJP) prophylaxis with co-trimoxazole](https://onco.cc/protocols/pneumocystis-pneumonia-prophylaxis/)
- pairings: [Caution: DXd ADC + agents with pneumonitis risk](https://onco.cc/pairings/ild-overlap-caution/)
- drugs: [Abemaciclib](https://onco.cc/drugs/abemaciclib/), [Datopotamab deruxtecan](https://onco.cc/drugs/datopotamab-deruxtecan/), [Everolimus](https://onco.cc/drugs/everolimus/), [Methylprednisolone](https://onco.cc/drugs/methylprednisolone/), [Olaparib](https://onco.cc/drugs/olaparib/), [Osimertinib](https://onco.cc/drugs/osimertinib/), [Ribociclib](https://onco.cc/drugs/ribociclib/), [Sotorasib](https://onco.cc/drugs/sotorasib/), [Trastuzumab deruxtecan](https://onco.cc/drugs/trastuzumab-deruxtecan/)
- terms: [CTCAE toxicity grading (grade 3-4 adverse events)](https://onco.cc/terms/ctcae-grading/), [Interstitial lung disease (ILD) / pneumonitis](https://onco.cc/terms/ild/), [Pneumonitis](https://onco.cc/terms/pneumonitis/), [Radiation pneumonitis and lung fibrosis](https://onco.cc/terms/radiation-pneumonitis/)

---
JSON: https://onco.cc/api/v1/entities/interstitial-lung-disease-on-antibody-drug-conjugates-and-targeted-drugs.json